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Toll-like receptors (TLRs) belong to the pattern recognition receptor (PRR) family, a key
component of the innate immune system. TLRs detect invading pathogens and initiate
an immediate immune response to them, followed by a long-lasting adaptive immune
response. Activation of TLRs leads to the synthesis of pro-inflammatory cytokines and
chemokines and the expression of co-stimulatory molecules. TLR4 specifically recog-
nizes bacterial lipopolysaccharide, along with several other components of pathogens and
endogenous molecules produced during abnormal situations, such as tissue damage. Evo-
lution across species can lead to substantial diversity in theTLR4’s affinity and specificity to
its ligands, the TLR4 gene and cellular expression patterns and tissue distribution. Conse-
quently,TLR4 functions vary across different species. In recent years, the use of synthetic
TLR agonists as adjuvants has emerged as a realistic therapeutic goal, notably for the
development of vaccines against poorly immunogenic targets. Given that an adjuvanted
vaccine must be assessed in pre-clinical animal models before being tested in humans,
the extent to which an animal model represents and predicts the human condition is of
particular importance. This review focuses on the current knowledge on the critical points
of divergence between human and the mammalian species commonly used in vaccine
research and development (non-human primate, mouse, rat, rabbit, swine, and dog), in
terms of molecular, cellular, and functional properties of TLR4.
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INTRODUCTION
Toll-like receptors (TLRs) are among the most studied of the
pattern recognition receptor (PRR) families and TLR4 is one
of the most studied TLRs. TLR4 specifically recognizes bacter-
ial lipopolysaccharide (LPS) and its activation mainly leads to the
synthesis of pro-inflammatory cytokines and chemokines (1, 2).
In recent years, the use of synthetic TLR agonists to preferentially
stimulate T-helper 1 (Th1) or Th2 immune responses has emerged
as a realistic therapeutic goal (2, 3). For example, the TLR4 agonist
monophosphoryl A (MPL), a derivative of LPS, has been approved
as an adjuvant for human vaccines against hepatitis B and human
papilloma virus (4, 5). Other TLR4 agonists are being developed
as adjuvant in clinical trials. For instance, GLA (glucopyranosyl
lipid adjuvant), a synthetic lipid A, is currently under test in a
formulation of stable emulsion (SE) in candidate vaccines against
tuberculosis (6). A phase I trial of GLA/SE adjuvanted H5N1 vac-
cine is complete (7). Such novel and safe adjuvants may facilitate
the development of vaccines against poorly immunogenic targets.
Before being tested in humans, an adjuvanted vaccine must be
assessed in pre-clinical animal models for safety and efficacy. Such
studies are commonly performed in rodents as well as in other
animal species. Thus, the extent to which an animal model repre-
sents and predicts the human condition is particularly important.
The ability of pathogens to evolve quickly has exerted strong evo-
lutionary pressure on the mammalian immune system to adapt in
parallel. Due to the various pathogens faced by humans and mice,
for example, many aspects of the innate and adaptive immune
systems of these two species are known to differ. Thus, human
and murine responses to TLR activation have some similarities
but also profound differences (8). These differences may affect
the predictive value of mouse models for immunological stud-
ies, making extrapolation from mouse data to human difficult to
achieve. Nevertheless, despite the divergent TLR sequences among
species, the basic biological function and down-stream signaling
pathways appear to be considerably conserved (Figure 2) (9, 10).
This review focuses on the critical points of divergence between the
mammalian species commonly used in vaccine research and devel-
opment, particularly in terms of TLR4 gene, expression patterns,
and functionality in innate immunity.
TLRs, first identified in human in the 1990s, are members of
the type-1 transmembrane receptor family and are evolutionarily
conserved proteins among vertebrates and invertebrates (11–13).
TLRs are characterized by an extracellular leucine-rich repeat
(LRR) domain involved in ligand recognition and an intracellu-
lar toll/interleukin-1 (IL-1) receptor-like (TIR) domain, the latter
of which is a highly conserved protein–protein interaction motif
module crucial for signal transduction (1, 2). The expression, lig-
and recognition, and signaling pathways of TLRs, as well as the
immune consequences of their activation have been described at
length elsewhere (2, 14, 15).
In 1999, Qureshi et al. identified the TLR4 gene in the LPS
chromosomal region as responsible for the defective LPS response
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in some mouse strains. They also identified independent muta-
tions in the TLR4 genes of two LPS-hypo-responsive mouse strains
(C3H/HeJ and C57BL10/ScCr), strongly suggesting that TLR4 is
essential for mediating responses to LPS in vivo (16, 17).
In addition to the recognition of LPS, a major component
of the outer membrane of Gram-negative bacteria, TLR4s from
various species (e.g., humans and mice) recognize several other
components of pathogens such as mannuronic acid polymers from
Gram-negative bacteria (18), teichuronic acid from Gram-positive
bacteria (19), and viral components such as the F protein of respi-
ratory syncytial virus (20, 21). In addition to exogenous PAMPs,
TLR4 also binds endogenous molecules such as heat shock pro-
teins in the mouse (22, 23), in the rat (24), and in the human (25).
Fibronectin type III extra domain A (26, 27) and saturated fatty
acids (28, 29) are potentially recognized by human and mouse
TLR4, and heme by mouse TLR4 (30). Recently, Choi et al. iden-
tified cholesteryl ester hydroperoxides, the active components of
minimally modified low-density lipoprotein (mmLDL), as a new
class of endogenous mouse TLR4 agonists (31). These findings
indicated that molecules produced or circulating during abnor-
mal situations, such as during tissue damage, are able to trigger
TLR4-dependent pathways (13).
Structurally, TLR4 forms a complex on the cell surface with
several other proteins needed for ligand recognition (e.g., LPS)
(1, 13, 32, 33). In the serum, LPS is initially bound by LPS
binding protein (LBP), which transfers LPS to CD14. CD14 is
a glycosylphosphatidylinositol-anchored membrane protein that
also exists in a soluble form and that binds LPS–LBP complexes
with high affinity. While CD14 itself lacks an intracellular domain
for signaling, it associates with TLR4 to form a functional LPS
receptor complex. Binding of LPS also requires the MD-2 pro-
tein, which associates with the extracellular domain of TLR4 (34).
Thus, the active LPS receptor complex includes CD14, TLR4, and
MD-2 (Figure 1), although further study suggests that CD14 and
LBP only enhance the TLR4-dependent LPS signaling and are not
absolutely required for LPS binding and signaling (35).
TLR4 ligands appear to bind the TLR4/MD-2 complex rather
than TLR4 alone. It is possible that MD-2 partially determines
the binding specificity of the TLR4/MD-2 receptor complex for
LPS variants and consequently affects TLR4 function in different
animal species (35, 36). Thus, paying special attention to MD-2
activities across species may be informative in investigations of
TLR4 function and in identifying relevant animal models.
TLR4 SIGNALING
MyD88-DEPENDENT AND MyD88-INDEPENDENT SIGNALING
PATHWAYS
TLR4 signaling pathways have been reviewed extensively by others
(14, 15, 32, 37, 38). Briefly, upon ligand binding at the cell surface,
TLR4 receptors homodimerize through interactions between their
intracellular TIR-domains, resulting in conformational changes
in the molecule. The subsequent signaling process involves the
recruitment of TIR-domain-containing adapter molecules to the
cytoplasmic face of the TLR4 cluster via homophilic interactions
between the TIR-domains. Four TIR-domain-containing adapter
molecules belonging to two distinct pathways are known to medi-
ate TLR4 signaling: Myeloid differentiation factor 88 (MyD88);
MyD88-adapter-like (Mal) protein, also known as TIR-domain-
containing adapter protein (TIRAP); TIR-domain-containing
adapter inducing interferon-β (TRIF), also called TIR-domain-
containing adapter molecule-1 (TICAM-1); TRIF-related adapter
molecule (TRAM), also called TIR-containing protein (TIRP), or
TIR-containing adapter molecule-2 (TICAM-2). TLR4 requires
all four of these adapters to mediate a comprehensive immune
response.
TLR4 initiates intracellular signaling by at least two major
pathways: (i) the TIRAP–MyD88 pathway, which regulates early
NF-κB activation and related inflammatory cytokine production,
such as IL-12; and (ii) the TRIF–TRAM pathway, which acti-
vates the interferon regulatory factor-3 (IRF3) transcription factor
that effectuates the subsequent up-regulation of genes encod-
ing type I interferons (IFNs) and co-stimulatory molecules. This
TRIF-dependent pathway also activates TNF-α production and
secretion. The subsequent binding of secreted TNF-α to its recep-
tors leads to NF-κB activation. Thus, the TRIF–TRAM pathway is
also responsible for the late phase NF-κB activation through IRF3
FIGURE 1 | LPS sensing via LBP and the CD14/MD-2/TLR4 receptor
complex. TLR4 consists of an extracellular domain with leucine-rich repeats
(LRR), a hypervariable domain (HYP), a transmembrane domain (TM), and a
cytoplasmic domain with a highly conserved TIR-domain. After binding to LBP
in serum, LPS is transferred to CD14 and then to the MD-2/TLR4 complex.
This illustration is based on mouse and human TLR4 knowledge.
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FIGURE 2 |TLR4 intracellular signaling cascade. The MyD88-dependent
pathway induces NF-κB translocation and expression of pro-inflammatory
cytokine genes. The MyD88-independent pathway induces NF-κB or IRF3
translocation, leading to expression of pro-inflammatory cytokine genes by
NF-κB or IFN-β and TNF-α genes by IRF3. This canonical signaling pathway is
based on published mouse and human TLR4 knowledge.
and TNF-α secretion (Figure 2). MyD88-independent signaling
accounts for the majority of the LPS response. The MyD88-
independent pathway results in the induction of dendritic cell
(DC) maturation (consequent to the expression of the genes
encoding co-stimulatory molecules such as CD40, CD80, and
CD86) and elevated expression of type-1 interferon genes and
of IFN-regulated genes (14, 32, 39).
SARM: TLR4 SIGNALING PATHWAY INHIBITOR
A fifth TIR-domain-containing adaptor, SARM (sterile alpha and
HEAT/Armadillo motif), was characterized (38, 40). Expression
of the gene encoding SARM is induced by LPS-mediated acti-
vation of TLR4 (41). SARM strongly inhibits TRIF-mediated,
but not MyD88-mediated, activation of NF-κB. In resting cells,
SARM and TRIF appear to interact weakly with each other. Fol-
lowing TLR4 activation, this interaction stabilizes and the resulting
complex prevents TRIF from interacting with other TLR adapter
proteins. Consequently, SARM is a negative regulator of TRIF-
mediated TLR signaling. This negative modulation may prevent
innate immune cells from an excessive activation in response to
LPS that may lead to lethal septic shock.
MOLECULAR, CELLULAR, AND FUNCTIONAL PROPERTIES OF
TLR4 ACROSS DIFFERENT MAMMALIAN SPECIES
SIMILARITIES AND DIFFERENCES IN TLR4 GENE AND AMINO ACID
SEQUENCES ACROSS SPECIES
Adaptive evolution is particularly prevalent in immune response
genes as a result of the sustained selective pressure exerted by
rapidly evolving pathogens (8). Mutations in the TLR4 gene can
inhibit the immune responses against the pathogens specifically
recognized by the ancestor receptor. In this regard, gene evolu-
tion across species can lead to different TLR4 gene expression
patterns or changes in the receptor’s affinity and specificity to
its ligands. Consequently, polymorphisms in the coding or pro-
moter sequence of TLR4 in different species may lead to different
resistance/susceptibility patterns to infectious diseases (10, 42).
Human TLR4 gene is composed of three exons. Their alignment
to the TLR4 protein is illustrated in Figure 3.
As indicated in Table 1, TLR4 genes are highly conserved across
mammalian species. Among different TLR4 sub-regions, the intra-
cellular TIR-domain is highly conserved across species suggesting
that the signal transduction pathways of TLR4 are also similar
across species. By contrast, TLR4 extracellular domains exhibit
considerable sequence divergence and the LRRs are highly poly-
morphic (10, 42, 43). Species-specific LRR variants in TLR4 may be
due to variations in the ligand-binding process and to the different
roles of the TLR4 co-receptor molecules. For example, Lizundia
et al. described a species-specific restriction in LPS recognition,
potentially due to differences in the binding of MD-2 to the LRRs
of the TLR4s of different species (35).
Pair-wise alignment of the extracellular domain of human
TLR4 with those of other species indicates that the most diver-
gent region of TLR4 is its ligand recognition domain, in which
different species exhibit a wide variety of surface electric charge
(42–44). The first 82-amino acids of the proximal region of the
TLR4 extracellular domain are poorly conserved across species
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FIGURE 3 | Alignment of humanTLR4 gene and protein. Exon 1 encodes a
signal peptide and initial amino acids of the extracellular domain. Exon 2
encodes first LRRs in the extracellular domain. Exon 3 encodes the remaining
extracellular domain (hypervariable region and LRRs), the transmembrane
domain and the cytoplasmic domain. TM, transmembrane domain; HYP,
hypervariable region.
Table 1 | Identity (%) between exon 1-cds, exon 2, and exon 3-cds
nucleotide sequences of humanTLR4 gene and that of various animal
species [based on data from Ref. (42)].
Animal
species
Pig Mouse Gorilla Orangutan Chimpanzee Baboon
Exon 1-cds 80 75 93 92 100 87
Exon 2 87 77 99 99 100 97
Exon 3-cds 81 74 99 97 99 94
and are highly variable for individuals in the same species. This
82-amino acid hypervariable region is known to be involved in
species-specific recognition of several TLR4 ligands as discussed
later in Section “Expression Pattern and Functionality of TLR4
Across Species – Mouse”.
Human
The human TLR4 gene maps to chromosome 9q32–33 (16),
SSC9:119.5 (45) and is composed of three exons (42) (Table 2). Its
pre-mRNA sequence is 11467 base pairs (bp) long from the 5′ cap
to the 3′ end of the transcribed sequence (46). The human TLR4
consists of an extracellular domain of 624 amino acids (residues
1–624), a transmembrane domain of 33 amino acids (residues
625–658), a proximal cytoplasmic domain of 159 amino acids
(residues 659–818), and a distal cytoplasmic domain of 19 amino
acids (residues 819–838). The ectodomain consists of 21 LRRs
(amino acids 55–569 of the extracellular domain) (47). Two TLR4
mRNAs of ~5.5 kb and 4.4 kb in size can be detected in all tis-
sues and are created by alternative splicing of the 3′UTR domain
of the pre-mRNA transcript (17). The human TLR4 also displays
many single nucleotide polymorphisms (SNPs) particularly in the
ectodomain of the protein,although most of these have only mildly
deleterious phenotypic effects (48).
Non-human primate
TLR4 of non-human primates (NHP) bears great similarity to
its human counterpart (Table 1) (46). However, some differences
exist even among NHPs. For instance, humans and chimpanzees
are generally considered to be very sensitive to LPS, whereas
baboons are highly resistant (46, 49). The human and chimpanzee
TLR4 amino acid sequences share 99–100% identity, irrespective
of the domain, distinguished by only three substitutions, except for
the 82-amino acid hypervariable regions, which are 98% identical
Table 2 | Comparison of the organization of human, porcine, and
murineTLR4 genes.
Animal species Human Pig Mouse
Exon 1-cds 93a 93 93
Intron 1 3996 3866 5972
Exon 2 167b 167 167
Intron 2 3638 2582 5168
Exon 3-cds 2260 2265 2251
Exon 3-3′-UTR 1127 568 1313
Values are in base pairs.
aSame as the pygmy chimpanzee, and olive baboon gene.
bSame as the gorilla, orangutan, pygmy chimpanzee, and olive baboon gene. Data
from Ref. (42).
(44, 46). The baboon and human TLR4 amino acid sequences
share 91.5% similarity in the extracellular domain and 85% sim-
ilarity in the 82-amino acid hypervariable region. The baboon
TLR4 transmembrane domain sequence differs from the human
sequence in one out of 30 residues,and in the proximal cytoplasmic
domain by only 1 out of 155 amino acids. The carboxyl terminal
domain is less similar to its human counterpart, with 16 of the last
21 human residues not replicated in the baboon protein, resulting
in a protein that is 13 amino acids shorter than the human protein
(Table 3). The authors suggested that this variation in the distal
cytoplasmic region of TLR4 might be a reason for interspecies dif-
ferences in LPS sensitivity. However, since TIR is instead located
in the proximal cytoplasmic region, whether such mutations were
functionally essential was in question (46).
The amino acid sequences of the NHP TIR-domains have not
been altered in the course of evolution. Indeed, most mutations in
these TIR-domains would likely have been deleterious. The TIR-
domains of the rhesus macaque display a high level of similarity
with their respective human counterparts with only two differ-
ences out of 169 amino acids. No differences are found between
the gorilla and human TIR-domains of TLR4 (49).
Mouse
The mouse TLR4 gene maps to chromosome 4, SSC4:66.5 (45) and
is made up of three exons (42) (Table 2). The mouse gene pro-
duces a longer pre-mRNA sequence than its human counterpart,
i.e., 15337 bp versus 11467 bp, respectively (46). Each murine
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Table 3 | Sequence similarity (%) between the amino acid sequences
of humanTLR4 and those of the chimpanzee, baboon, mouse, rat, and
rabbit [based on data from Ref. (44, 46, 47)].
Animal species Chimpanzee Baboon Mouse Rat Rabbit
Distal extracellular
domain
100 95 66 66 77
Hypervariable region 98 85 48 39 57
Proximal
extracellular domain
100 93 63 64 63
Transmembrane
domain
100 97 70 68 75
Proximal cytoplasmic
domain
99 99 90 92
85
Distal cytoplasmic
domain
100 50 26 38
exon corresponds to a homologous sequence in the human gene.
A number of conserved promoter and enhancer motifs can be
aligned in the murine and human 5′ flanking sequences. Murine
and human TLR4 share 67–71 and 79–81% similarity at the
nucleotidic and amino acid levels, respectively (17, 35). Amino
acid similarity between the mouse and human TLR4 sequences
is 62% in the extracellular domain, 70% in the transmembrane
domain, and 83% in the cytoplasmic domain (44, 46, 47). The 82-
amino acid hypervariable region is the least conserved between the
two species with only 48% similarity. In the cytoplasmic region,
the amino acid conservation between the mouse and human is
greater in the proximal domain (TIR-domain) (90%) than in the
distal domain (26%) (Table 3). In the TIR-domain, only 12 out
of 169 amino acids differ between the mouse and human TLR4
sequences (49). The human and murine promoter sequences share
only 53% similarity and the components involved in the regulation
of gene expression display significant differences (1, 42).
The murine and human MD-2 proteins share mere ~57%
amino acid similarity (47). Mouse MD-2 also displays some dis-
crete structural differences relative to the human counterpart in
terms of electric charge properties (36). Human MD-2 is more
cationic than mouse MD-2. This disparity includes residues close
to the LPS binding site that are positively charged in the human
MD-2. These differences impact not only the secretion but also
the function of MD-2, thus the activation of TLR4.
Across mouse strains, the TLR4 locus exhibits some genetic
variations too. Among 35 strains of Mus musculus, 10 different
alleles are identified on the basis of mutations at 22 sites, compared
to a common reference sequence (46). Some strains have accumu-
lated more mutations than others. For example, the LPS-tolerant
C3H/HeJ strain harbors a single C to A transversion point muta-
tion, which results in a non-conservative amino acid substitution
(proline 712 to histidine 712) within the cytoplasmic domain of
TLR4 (16, 17, 46). This substitution is expected to alter the topol-
ogy of the TLR4 signaling domain and potentially disrupt protein–
protein interactions with down-stream molecules. Indeed, the
P712H substitution in TLR4 results in a co-dominant inhibitory
effect on LPS signal transduction. Another endotoxin-tolerant
strain is the C57BL/10ScCr mouse, which harbors a genomic
deletion in the Lps locus and does not produce a TLR4 transcript
or a TLR4 protein. These observations support the hypothesis that
their mutant phenotype is due to a loss of TLR4 function.
The C57Bl/6J, DBA2, BALB/c, C3H/ARC, and C3H/HeJ mouse
strains differ in at least two genetic loci known to influence
innate immune responses (50). The C3H/HeJ strain is known
to be LPS hypo-responsive, whereas the other four strains are
LPS sensitive. Four hundred fifteen genes are identified by cDNA
microarray analysis as LPS-inducible and temporally regulated in
bone marrow-derived macrophages of the four LPS-responsive
strains. These genes are not regulated by LPS in cells from the
C3H/HeJ mice. Thus, this set of genes represents possible down-
stream targets specific to TLR4 signaling pathways. The DBA2
and C57Bl/6J mouse macrophages share a similar temporal pro-
file of LPS-inducible gene regulation, but the gene induction is
delayed in the BALB/c and C3H/ARC macrophages. Most of the
genes induced encode components of the cytoskeleton or the
phagosome, which correlates with the morphological changes that
occur in bone marrow-derived macrophages upon LPS stimula-
tion. Thirty elements corresponding to 22 genes involved in cell
growth, cycling, and differentiation belong to the TLR4-dependent
transcriptional pathway.
Rat
In the extracellular domain of TLR4, rats and humans share 61%
overall amino acid similarity (46). The 82-amino acid hypervari-
able region is the least conserved with only 39% amino acid
similarity, whereas the similarity is ~65% for the remainder of
the extracellular domain (44). Amino acid similarity is 68% in
the transmembrane domain, 92% in the proximal cytoplasmic
region, and 38% in the distal cytoplasmic region (46) (Table 3).
Rats and humans display 10 amino acid differences in the TLR4
TIR-domain out of 169 amino acids (49).
Rabbit
Comparing to the mouse and rat, the TLR4 and MD-2 proteins
from the rabbit are highly similar to their human counterparts,
with 72 and 70% amino acid similarity, respectively (47, 51). In the
TLR4 extracellular domain, the distal region displays the greatest
shared similarity (77%), whereas the 82-amino acid hypervariable
region displays the lowest similarity (57%). The cytoplasmic and
transmembrane domains of the rabbit TLR4 share 85 and 75%
similarity respectively to their human counterparts (Table 3).
Because the amino acid similarity shared with the human 82-
amino acid hypervariable region is greater in the rabbit than in the
mouse, the rabbit TLR4 may recognize human pathogens better
than the mouse TLR4 (47). This, and the greater overall simi-
larity between rabbit and human TLR4, suggests that the human
immune response to some pathogens may be better modeled in
rabbits than in mice.
Swine
The porcine TLR4 gene maps to chromosome 1, SSC1:284.7 (45).
As in humans and mice, the porcine TLR4 gene is made up of
three exons. The open reading frame (ORF) of 2526 bp encodes
841-amino acid protein (42). The first exon includes a 98 bp 5′-
UTR and the first part of the coding sequence; the third exon
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encodes the last 754 amino acids of the TLR4 protein along
with a 568 bp 3′UTR (Table 2). Overall, the predicted porcine
TLR4 protein contains a 23-amino acid putative leader peptide,
an extracellular domain of 608 residues (24–632), a hydrophobic
transmembrane region of 21 residues (633–653), a proximal cyto-
plasmic region (654–672), and a cytoplasmic TIR-domain of 147
residues (673–819). The extracellular domain includes 21 LRRs of
20 to 29 residues (42, 52).
Porcine and human TLR4 nucleotide sequences share 65-77%
similarity (51). The porcine TLR4 amino acid sequence is 63–
80% similar to the complete human, rabbit and mouse TLR4
sequences. Again, most of the amino acid differences among these
species are located in a region between residues 285 and 366, which
corresponds to the 82-amino acid hypervariable region involved
in ligand recognition (52). In the cytoplasmic portion, the TIR-
domain is the most conserved segment and is over 90% similar to
the human, rabbit, and mouse TIR-domains. Porcine and human
promoter sequences are 71% similar. Overall, the porcine TLR4
promoter shares more features with the human TLR4 promoter
than its murine counterpart (42).
Dog
The full-length cDNA sequence of canine TLR4 (2709 bp) con-
tains a 5′ UTR (1–194 bp), a long ORF (195–2105 bp), a 3’ UTR
(2106–2687 bp) and encodes a protein of 637 amino acids (53).
Canine TLR4 is 70–77% similar to the human TLR4 nucleotide
and amino acid sequences, and is highly similar to the sequences
of other mammalian TLR4s. However, the canine gene lacks the
two first exons found in other TLR4 genes (42, 53). Sequence
alignment confirms that this is not due to a loss of introns or a dif-
ferent exon sequence organization (Accession numbers: Genbank
O00206 and Genbank BAB85609.1).
EXPRESSION PATTERN AND FUNCTIONALITY OF TLR4 ACROSS SPECIES
Despite extensive sequence similarity among mammalian TLR4s,
species-specific variations in their extracellular domains cause
these receptors to have different spectrums of agonists and antago-
nists. In addition, there is substantial diversity in the TLR4 cellular
expression pattern and tissue distribution. Consequently, TLR4
functions vary across different species (35). Table 4 summarizes
the TLR4 expression patterns in the following species: humans,
NHP, mice, rats, swine, rabbits, and dogs.
Human
The predominant TLR4 expressing cells in humans are of myeloid
origin. Analyses of total RNA showed that TLR4 mRNA was
present only in myeloid cells and was undetectable in resting or
activated lymphoid cell subsets. Human plasmacytoid dendritic
cells (pDCs) do not express TLR4 (9, 54–56). Human B cells
were thought to lack significant TLR4 expression, at least in the
naïve resting state, and were thus considered to be unresponsive to
LPS (9, 57). However, TLR4 expression in human B cells may be
inducible by specific stimuli, such as IL-4, suggesting that B cells
can be rendered sensitive to TLR4 ligands (58).
Characteristic patterns of TLR4 and MD-2 expression are
observed in monocytes, immature DC, and mature DC. Mono-
cytes produce a high level of TLR4 mRNA (54). This TLR4 expres-
sion level decreases markedly during immature DC formation but
remain clearly detectable (59). Further DC maturation is associ-
ated with a loss of TLR4 expression and the consequent loss of
LPS responsiveness. The inverted MD-2/TLR4 ratios in mono-
cytes and DCs suggest that MD-2 might limit the LPS response in
monocytes whereas TLR4 would limit DC response. DC activation
by TLR4 agonists induces up-regulation of the genes encoding
IL-12 p70, IP-10, and IFN-β (60). Exposure of monocytes and
granulocytes to LPS or to pro-inflammatory cytokines increases
the expression of TLR4 (55). Similarly, stimulation of THP-1 (a
monocyte-like leukemic cell line) by PMA (phorbol 12-myristate
13-acetate) increases the sensitivity of these cells to LPS that cor-
relates with marked increases in TLR4, CD14, MD-2, and MyD88
mRNA levels (56). In addition to the classical increase of TLR4
expression by PAMPs, TLR4 expression in monocytes may also be
regulated by glucose, as high concentrations of glucose but not
mannitol induce TLR4 mRNA and protein expression and TLR4
activation (61, 62).
In human tissues, the highest levels of TLR4 mRNA detected by
PCR are in the spleen and PBLs. Moderate levels of TLR4 expres-
sion are detected in the colon, ovary, lungs, small intestine, and
placenta, whereas TLR4 expression is low in the brain, heart, kid-
neys, liver, prostate, pancreas, testis, muscle, and thymus. No TLR4
expression was detected in skeletal muscle or skin (53, 56, 62).
Further investigations using for example immunohistochemistry,
could help to determine whether TLR4 is expressed by tissue cells
or by cells of blood origin, in particular for organs like liver and
lungs. TLR4 is constitutively expressed in the human fat tissue
with a clear detection in adipocytes, and its expression is not reg-
ulated following LPS treatment (63). Nevertheless, stimulation of
mature adipocytes with a TLR4 agonist increases TNF-α protein
concentrations. Since mature adipocytes do not express CD14, the
activation of TLR4 on these cells likely requires exogenous CD14.
In cultured human corneal epithelial cells and corneal stromal
fibroblasts, Acanthamoeba challenge up-regulated TLR4 expres-
sion, and induced an early production of IL-8 and TNF-α through
the TLR4/NF-κB pathway and later production of IFN-β through
the TLR4/Erk1/2 pathway (64).
In the human central nervous system (CNS), TLR4 is expressed
by two types of non-neuronal supportive cells: the CNS residential
macrophages or microglia and the macroglial cells such as astro-
cytes (65). In microglia, TLR4 protein is localized within intracel-
lular vesicles and is undetectable on the cell surface (only ~15%
of microglia cells express TLR4). Astrocytes and oligodendrocytes
also slightly express TLR4. In astrocytes, TLR4 is exclusively local-
ized on the cell surface and is not detectable within intracellular
vesicles. This difference in the TLR4 subcellular localization may be
linked to the different phagocytic and antigen processing proper-
ties of microglia and astrocytes. Development of multiple sclerosis
lesions in humans is associated with higher levels of TLR4 expres-
sion. The TLR4 mRNA level increases in a human brain endothelial
cell line following oxidative stress (66). TLR4 may be involved in
cardiovascular diseases. For example, elevated levels of TLR4 have
been found in the tissues of failed hearts and ischemic hearts (67).
Non-diabetic human β-cells contain TLR4 and CD14 tran-
scripts (62). Pancreatic islets subjected to flow cytometric analysis
displayed variable levels of TLR4 protein on the cell surfaces, with
the TLR4 found almost exclusively on insulin-producing β-cells.
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Table 4 |TLR4 expression across species.
Organs Human Non-human primate Mouse Rat Swine Rabbit Dog
PBL +++ +++ +++ ND ND ND +++
Myeloid subsets +++ +++ +++ ND ND ND ND
Monocytes +++ ND +++ + +/− ND ND
Macrophages +++ ND +++ ND +/− ND ND
Granulocytes +++ ND +++ ND ND ND ND
Dendritic cells +++ +/++ ND ND
Immature dendritic cells + + + ND +++ ND ND
Mature dendritic cells − − ND ND +++ ND ND
Plasmacytoid dendritic cells − − + + ND ND ND
Lymphoid subsets +/− +/− ++ ND ND ND ND
Adipocytes ++ ND ND ND ND ND ND
Brain + ND ND + + ND
Basilar artery ND ND ND ND ND + ND
Hypothalamus ND ND ND ND + ND ND
Hippocampus ND ND ND ND + ND ND
Cortex ND ND ND ND + ND ND
Cerebellum ND ND ND ND + ND ND
Microglia ++ ND ++ ++ ND ND ND
Astrocytes + ND − +/− ND ND ND
Neurons ND ND ND +/− ND ND ND
Oligodendrocytes + ND − − ND ND ND
Cornea ND ND ND + + ND +
Endothelium
Dermal microvessel endothelium ++ ND ND ND ND ND ND
Umbilical vein endothelium ++ ND ND ND ND ND ND
Lung endothelium ND ND ND ND ND ++ ND
Brain endothelial cell line ++ ND ND ND ND ND ND
Primary brain endothelial cells ND ND ND ++ ND ND ND
Heart + ND +++ + ND + ND
Intestine
Small Intestine ++ ND ND ND +/++ ND ++
Colon ++ ++ ND ND ++ ND +
Jejunum ND ND ND ND +/++ ND ND
Ileum ++ ++ ND ND ++ ND ++
Duodenum ND ND ND ND ND ND ++
Intestinal epithelial cell lines ++ ND ND ND ND ND ND
Mesenteric lymph node ND ND ND ND ND ND +++
Kidney + ND ++ ND + ++ +/−
Liver + ND ++ ND + + +
Kupffer cells ND ND ND ND + ND +
Hepatocytes ND ND ND ND − ND −
Vascular endothelium ND ND ND ND − ND −
Bile duct epithelium ND ND ND ND + ND +
Lung ++ ND +++ ND + ++ +
Macrophages ND ND ND ND + ++ +
Epithelial cells ND ND ND ND + − +
(Continued)
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Table 4 | Continued
Organs Human Non-human primate Mouse Rat Swine Rabbit Dog
Lymph node ND ND ND ND ++ ND ND
Ovary ++ ND ND ND + ND ND
Pancreas + ND + ND ND ND ND
Insulin-producing β-cells + ND + ND ND ND ND
Glucagon-secreting α-cells +/− ND ND ND ND ND ND
Placenta ++ ND ND ND ND ND ND
Prostate + ND ND ND ND ND ND
Skeletal muscle − ND ND ND −/+ ND −
Skin − ND ND ND − ND −
Smooth muscle + ND ++ ND − ND −
Spleen +++ ND +++ ND ++/+++ ++ ++
Stomach ND ND ND ND ND ND ++
Testis + ND ND ND ND ND ND
Tonsil ND ND ND ND ++/+++ ND ND
Thymus + ND ND ND ++ +/− ND
Summary of TLR4 expression patterns in the human, non-human primate, mouse, rat, swine, rabbit, and dog to our knowledge (see text for references, ND, not
described).
TLR4 and CD14 expression increased following LPS exposure in
a dose-dependent manner. In the presence of LPS-induced TLR4
expression in β-cells, insulin mRNA, insulin secretion, and cell
viability decrease.
Human dermal microvessel endothelial cells (HMEC) and
human umbilical vein endothelial cells (HUVEC) express TLR4
(68). However, unlike monocytes, macrophages, and pancreatic
β-cells, endothelial cells do not express CD14. Thus, activation of
endothelial cells by LPS requires the presence of soluble CD14 in
the serum. Expression of TLR4 has been also detected in intesti-
nal epithelial cell lines (69, 70). Although normal human ileal
epithelium barely expresses TLR4, its expression is up-regulated in
inflammatory bowel disease (IBD). This phenomenon may explain
why large quantities of luminal LPS are usually well tolerated by
healthy intestine since the low levels of TLR4 minimize LPS recog-
nition. However, this tolerance toward luminal bacterial toxins
may be broken during IBD as a result of TLR4 up-regulation.
Non-human primate
Although the currently available evidence is limiting, no funda-
mental differences between humans and NHPs at the level or
pattern of TLR4 expression have been reported. Blood DC sub-
sets, DCs derived from monocytes in vitro (mo-DCs), monocytes,
and B cells of rhesus macaques display the same expression pat-
terns of TLRs (TLR3, -4, -7, -8, and -9) as those of humans (9).
Neither macaque nor human pDCs express TLR4. Consequently,
these pDCs do not undergo any differentiation or morphological
changes in response to stimulation with E. coli LPS. LPS exposure
of macaque monocytes induces CD40 expression and a high level
of TNF-α production, but no CD86 expression. LPS stimulation
of macaque myeloid DCs and mo-DCs up-regulates the expres-
sion of CD40 and CD86, but induces only low levels of TNF-α
production and no detectable IL-12p70. In addition, TNF-α and
IL-6 synthesis by macaque myeloid DCs and monocytes following
LPS exposure is regulated in an age-dependent manner (71).
For macaque PBMCs,Asquith et al. recently reported that TLR4
and SARM expression levels were lower in juvenile macaques
(1–7 years old) than in adult (5–18 years old) or aged animals
(≥19 years old) (71). As SARM is a negative regulator of TLR4
signaling by blocking TRIF binding to TLR4 adapter proteins (41,
72), a low level of negative regulation by SARM may compensate
the low level of TLR4 expression in young macaques and allow a
robust response to LPS.
Immunochemistry studies revealed that TLR4, MD-2, NF-κB,
and IRAK-1 are constitutively expressed at low levels in the ileal
epithelium of adult macaques (70, 73). Intestinal epithelial cells
normally restrict the entry of LPS in the circulation. However,
inflammatory or non-inflammatory (e.g., stress) conditions can
induce the translocation of LPS into the blood circulation. Given
that TLR4 is expressed in the apical membrane of ileal epithelial
cells, the presence of LPS in the ileal lumen may stimulate epithelial
cells through TLR4 and induce the production of chemoattractant
factors for neutrophils and inflammatory cytokines. LPS that has
been translocated from the villous epithelium can then be taken
up by neutrophils, which then migrate to the portal circulation via
the epithelium and lamina propria.
Data are limited regarding the function of TLR4 in NHP species
other than macaques. Nevertheless, species-specific similarities
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and differences have been noted among different NHP species.
For example, human and baboon arterial endothelial cells dis-
play a low but similar basal expression of TLR4 (74). However,
TLR4 expression is up-regulated by LPS only in the human cells.
In addition, only the human NF-κB pathway is activated upon
LPS exposure despite the fact that the NF-κB machinery is intact
in both human and baboon arterial endothelial cells. This could
explain why baboon arterial endothelial cells appeared being resis-
tant to the pro-inflammatory effects of LPS and the lack of vascular
response to LPS in baboons. This lack of activation of the TLR4
signaling pathway appears to be cell specific since human and
baboon PBMCs are similarly responsive to LPS.
Mouse
In mice, as in humans, cells of myeloid origin such as monocytes,
macrophages, microglia, myeloid DCs, and granulocytes exhibit
the highest levels of TLR4 expression. TLR4 is also expressed by
lymphoid cell types like naïve B cells and freshly isolated T cells.
However, in sharp contrast to human pDCs, murine pDCs express
high levels of TLR4 (9, 57, 75).
Minimally modified LDL (mmLDL), via its cholesteryl ester
hyperoxide moieties, increases macro-pinocytosis by mouse
macrophages in a TLR4-dependent manner (31). This leads to
lipid accumulation in macrophages. mmLDL also induces Syk
recruitment to TLR4. This process leads to actin polymerization, a
step required for membrane ruffling that likely promotes antigen
uptake. However, Syk-independent pathways may also contribute
to the TLR4-dependent antigen uptake. Altogether, these murine
data suggest an important pro-inflammatory role for mmLDL in
macrophage activation through a TLR4-dependent pathway.
Murine TLR4 mRNA is abundant in the lungs, heart, and spleen
and, as in humans, is sparse in the muscle, liver, and kidneys (10,
17, 53), although further investigation is needed to clarify the cell
types that express it in these tissues.
The TLR4 expression pattern in the mouse CNS differs from
the human in that only the microglia expresses TLR4. Neither
the mouse astrocytes nor oligodendrocytes do (65). In CNS cell
cultures, LPS induces significant injury to developing oligoden-
drocytes, only in the presence of microglia (76). As oligodendro-
cytes lack TLR4, these findings suggest that the activation of TLR4
signaling by LPS in microglia leads to indirect injury to oligo-
dendrocyte precursors, which are susceptible to reactive oxygen
species and pro-inflammatory cytokines.
Similar to humans, TLR4 is also involved in cardiovascular
diseases in mice (67, 77). Murine TLR4 is up-regulated after
myocardial infarction and is involved in myocardial dysfunction
during bacterial sepsis. TLR4 regulates maladaptive left ventricular
remodeling that occur post-infarction, probably via inflammatory
cytokine production and matrix degradation. Human and murine
pancreatic β-cells express TLR4 as well as CD14 (62). Exposing
β-cells to LPS causes the expression of these two molecules to
increase in a dose-dependent manner. In the presence of LPS-
induced TLR4 expression, in β-cells from both species, insulin
mRNA levels, insulin secretion, and the cell viability all decrease.
When infected with T. cruzi, liver TLR4 expression levels were
found being lower in the C57BL/6 mice than in the BALB/c
mice (78). The low level of TLR4 expression contributes to an
imbalanced production of pro- and anti-inflammatory cytokines
and might play a role in the fatal hepatic injury observed in the
infected C57BL/6 mice.
Multiple mouse TLR4 mRNA isoforms can be detected by
northern blot analysis (75). A 144-bp insertion between the sec-
ond and third exon is produced by an alternative splicing. This
novel exon contains an in-frame stop codon at 110 bp. The alter-
natively spliced mRNA encodes a soluble 20-kDa protein (122
amino acids) known as smTLR4 (soluble mouse TLR4), an antag-
onist to TLR4. smTLR4 mRNA can be detected in various tissues
including the brain, heart, lungs, kidneys, liver, thymus, spleen, and
small intestine. Although activation of mouse monocytes with LPS
causes little changes in the total level of TLR4 mRNA, LPS strongly
increases the level of mRNA for smTLR4. The alternatively spliced
variant contains a part of the extracellular domain of TLR4 that
interacts with LPS (56, 75). Thus, smTLR4 may compete with
TLR4 for LPS binding. smTLR4 may suppress LPS signaling by
interacting with CD14 and/or LBP or by inhibiting the TLR4/MD-
2 interaction. In addition to the secreted smTLR4, a significant
amount of smTLR4 is entrapped in the cell membrane, where it
may mediate antagonistic effects as well through interacting with
newly synthesized TLR4 or CD14 and thus blocking TLR4 sig-
nal transduction. As smTLR4 inhibits LPS-mediated signals and
smTLR4 mRNA synthesis is induced by LPS, one can hypothesize
that smTLR4 is involved in a negative feedback loop to prevent
an excessive LPS response. Interestingly, smTLR4 mRNA synthesis
also increases in T cells following TCR engagement. Thus, smTLR4
may also regulate the LPS response in T cells. Nonetheless, a human
counterpart of the smTLR4 remains to be confirmed.
Lipopolysaccharide increases TLR4 expression in human
macrophages and monocytes. In contrast, TLR4 expression
decreases in mouse peritoneal macrophages and neutrophils after
LPS challenge and remains unaffected in mouse monocytes (55,
79). Pre-exposure to LPS reduces cellular sensitivity to subse-
quent LPS challenge. This phenomenon, termed LPS tolerance,
is mainly due to the loss of surface TLR4 expression. LPS pretreat-
ment of mouse macrophages suppresses inflammatory cytokine
production in a time- and dose-dependent manner and signifi-
cantly reduces NF-κB DNA-binding activity (79). Schroder et al.
reported differences in the gene regulation of human and murine
macrophages following LPS stimulation (8). Although TLR4 tar-
get genes are more rapidly induced in human macrophages than
in mouse macrophages following LPS exposure, several negative
feedback regulators of the TLR4 pathway are more rapidly induced
and to a greater degree in mouse macrophages. This enhanced
negative feedback regulation may further reduce the primary LPS
response in mouse macrophages, thereby contributing to the lower
endotoxin sensitivity in mice compared to humans.
Another difference between mouse and human TLR4 probably
lies in the LPS recognition spectrum of the receptor complex. For
example, human TLR4, but not murine TLR4, can discriminate
between the hexa- and penta-acylated forms of LPS produced
by Pseudomonas aeruginosa from the airways of cystic fibrosis
patients. This discrimination is mediated by the 82-amino acid
hypervariable region of TLR4 (44). In addition, differences in
the primary structure of MD-2 across species can also lead to
changes in TLR4 binding specificities. Using different chimeric
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complexes consisting of human and mouse TLR4 and MD-2,
the MD-2-mediated TLR4 species-specific ligand recognition was
demonstrated for Taxol (80) and lipid IVa (a lipid A analog) (81).
Taxol, a chemotherapeutic drug derived from plants, acts as a TLR4
agonist on murine cells but not on human cells. Human cells dis-
criminate lipid IVa from lipid A and only respond to the latter,
whereas mouse cells respond similarly to both lipids. Lipid A is
the anchor moiety and active component of LPS. Variability in
its structure has also been found between bacterial species. For
instance, lipid A from E. coli stimulates human monocytes, lep-
tospiral lipid A does not. By contrast, the lipid A from Leptospira
activates murine cells (82). In 2009, Vasl et al. reported additional
functional differences between human and murine MD-2, includ-
ing the ability of human but not murine MD-2 to be secreted and
to function as an extracellular endotoxin-binding protein with or
without TLR4 (36).
Rat
In contrast to human pDCs, which do not express TLR4, TLR4
mRNA transcripts have been detected in all rat DC subsets (CD4+
and CD4− myeloid DCs and plasmacytoid DCs) and monocytes
from Sprague-Dawley, Lewis and Brown Norway rats. Monocytes,
pDCs, and CD4+DCs express low levels of TLR4, whereas CD4−
DCs express moderate levels of TLR4 (83). LPS increases the
survival but not the maturation of pDCs, while only modestly
enhancing their stimulatory capacities. CD4+ DCs are poorly
responsive to TLR4 ligands, whereas CD4−DCs exhibit increased
cell survival and maturation following TLR4 stimulation. Acti-
vated CD4− DCs in culture produce high concentrations of IL-
12p40, low concentrations of IL-10, very low concentrations of
TNF-α and no IL-6.
Normal rat cornea and cardiomyocytes express TLR4 (67, 84).
Similar to the behavior of cultured human corneal epithelial
cells, exposing the cornea of Wistar rats to Acanthamoeba up-
regulates the expression of TLR4 and inflammatory cytokines,
and activates the transcription of MyD88 and NF-κB genes (84).
In humans, TLR4 up-regulation is implicated in cardiovascular
diseases. In rats, TLR4 expression is enhanced during hyper-
tension (67). Compared to normotensive Wistar–Kyoto (WKY)
rats, spontaneously hypertensive rats (SHR) exhibit an enhanced
TLR4 distribution predominantly in cardiomyocytes. The TLR4-
positive cardiomyocytes in SHR rats homogenously express TLR4
on the membrane as well as in the cytoplasm. In compari-
son, TLR4 expression in WKY rat cardiomyocytes is restricted
to fewer cells and at a lower intensity on a single cardiomy-
ocyte basis. This enhanced TLR4 level in SHR rats is function-
ally associated with a higher TLR4-dependent pro-inflammatory
activity.
Primary rat brain endothelial cells slightly express the TLR4
mRNA under basal conditions (66). Rat brain expresses TLR4 and
its expression pattern evolves during the brain development. The
number of TLR4-positive cells is considerably lower in P3 and P5
(preterm human equivalents) rat brains than in P7, P9, or P14
(human early childhood equivalent) brains. Inflammatory events
often associate with oxidative stress, which in turn affects TLR
expression. As in human, oxidative stress induces TLR4 mRNA
synthesis in rat cerebral endothelial cells.
Rat microglia clearly expresses TLR4 and CD14. Similar to mice
but in contrast to humans, neither astrocyte nor oligodendrocyte
precursors express TLR4 in rats. Thus, microglia appears to be
the major cell type in the rat CNS able to transduce LPS signals
(76, 85). LPS-treated rat microglia from the forebrain induces
oligodendrocyte death. LPS does not affect the TLR4 expres-
sion in cultured glial cells but LPS-activated microglia produce
a wide variety of reactive oxygen species and cytokines. Similar
to the mouse, this could explain the microglia-mediated injury
to oligodendroglial precursors following LPS exposure since rat
oligodendroglial precursors are vulnerable to such mediators.
Rabbit
Different from human tissues, in which the highest levels of TLR4
expression are found in the spleen, the highest levels of TLR4
expression in rabbit tissues occur in the lungs and bone marrow.
TLR4 is moderately expressed in the kidneys, spleen, heart, and
liver and low levels are found in the thymus. TLR4 is constitutively
expressed in the normal basilar arteries of rabbits (47, 86).
TLR4 is up-regulated and activated in the basilar arterial wall
during cerebral vasospasm after experimental subarachnoid hem-
orrhage in rabbits, suggesting a role for TLR4-associated signaling
pathway in the pathogenesis and development of inflammation in
cerebral vasospasm (86). In the normal lungs of rabbits, alveolar
macrophages and endothelial cells, but not epithelial cells, were
shown to express TLR4 using immunochemistry analysis (47).
Granulocytes also expressed TLR4 but to a lesser extent when
compared to macrophages, epithelial cells, and endothelial cells.
Further studies using the more sensitive flow cytometry technol-
ogy indicated that TLR4 was located on the surface as well as in
the cytoplasm of alveolar macrophages and pulmonary epithelial
cells. It is plausible that a cytoplasmic pool of TLR4 allows rapid
transport of these receptors to the cell surface. TLR4 translocation
and an increased TLR4 gene transcription are therefore two likely
mechanisms responsible for the elevated TLR4 expression on the
surfaces of these cells observed in inflamed lungs or in the lungs
of rabbits suffering from Gram-negative pneumonia (47). The
TLR4/MD-2 levels in these infected animals also increase in the
bone marrow and kidneys and TLR4 expression is significantly up-
regulated in the spleen. Thus, TLR4 in the rabbit likely plays a criti-
cal role in the innate response to bacterial infection in the lungs and
likely is involved in preventing systemic dissemination of the infec-
tion. Mechanical ventilation increases the inflammatory response
to LPS via a CD14-independent, TLR4-dependent pathway, as
demonstrated using an anti-TLR4 monoclonal antibody (87).
Swine
Porcine monocytes, immature and mature mo-DCs express TLR4
transcripts, whereas human mature mo-DCs do not (52). In
porcine blood mononuclear cells, LPS induces or up-regulates
the transcription of TLR4, CD14, and MD-2 mRNAs, as well as
cytokine mRNAs such as IL-1, IL-10, IL-12, TNF-α, and IFN-γ.
Synthesis of IL-12p40, IL-6, IL-1β, IL-8, IL-10, and TNF-α pro-
teins also increases (88–90). A transcriptomic analysis of porcine
PBMCs stimulated in vitro with LPS indicated that most of
the up-regulated genes were involved in inflammation and the
innate immunity, including chemotactic factors targeting a broad
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spectrum of innate immune cells (91). Serum amyloid A, which
is involved in the establishment and maintenance of inflamma-
tion, was the most prominently up-regulated gene. In contrast,
LPS exposure induced a strong down-regulation of classical and
non-classical MHC-II genes. Although TLR4 expression increases
in human monocytes following LPS exposure, the same effect does
not occur in porcine monocytes (88).
Among organs, the highest levels of porcine TLR4 mRNA are
detected by PCR in the colon and spleen. However, TLR4 mRNA
is also found in the lungs, small intestine, liver, kidneys, thy-
mus, lymph nodes, brain (hypothalamus, hippocampus, cortex,
and cerebellum), tonsils, ovary, and cornea. As in humans, TLR4
mRNA is undetectable in porcine skin and skeletal muscle (42, 52,
92, 93). Immunohistochemistry studies have revealed that TLR4
in the lungs is expressed by macrophages and epithelium, in the
liver by Kupffer cells and by bile duct epithelium. However, nei-
ther hepatocytes nor hepatic vascular epithelium express it (93).
Porcine neonatal intestinal epitheliocytes (PIE) consistently pro-
duce TLR4 and MD-2 mRNAs with a high level of TLR4 protein
detected. LPS exposure of PIEs enhances the expression of TLR4,
pro-inflammatory cytokines, and chemokines (94). TLR4 is also
expressed in M cells and in gut-associated lymphoid tissues. In
pigs infected with porcine reproductive and respiratory syndrome
virus, TLR4 is up-regulated in tracheobronchial lymph node,
brain, hypothalamus, hippocampus and, to a lesser extent, in the
cortex and cerebellum. But it is not up-regulated in the lungs (95).
Dog
As in humans, the peripheral blood leukocytes of dogs express high
levels of TLR4 mRNA. Moderate levels are found in the canine
spleen, stomach, small intestine, lungs, and cornea, while low lev-
els in the liver and kidneys. No TLR4 expression was detected in the
skeletal muscle and skin (51, 53, 93). The presence of TLR4 mRNA
in canine large intestine is controversial. No mRNA was detected
by conventional RT-PCR (53) but a recent Real-Time RT-PCR
analysis let Burgener et al. detect TLR4 mRNA in both small and
large intestines (96). Among the mesenteric lymph nodes, stom-
ach, colon, duodenum, and ileum, the mesenteric lymph nodes
contained the highest amount of TLR4 mRNA and the colon con-
tained the least (96). Functional TLR4 was found constitutively
expressed at a low level in canine primary colonic epithelial cells
and rapidly up-regulated following TLR4 ligand exposure. Activa-
tion of TLR4 signaling in these cells by LPS results in secretion of
IL-8 and IL-7 (39, 51, 97).
As shown for swine, immunochemistry studies of canine tissues
have revealed that TLR4 in the lungs is expressed by macrophages
and epithelium, in the liver by Kupffer cells and bile duct epithe-
lium; but it is not expressed by hepatocytes or by vascular
epithelium (93).
Overall, due to limited available information describing TLR4
expression and functionality in the rat, swine, rabbit, and dog,
it is difficult to make comprehensive comparisons between these
species or to the human.
RESPONSE TO LPS ACROSS SPECIES
As discussed in this review, LPS is the primary natural ago-
nist to TLR4. It is important to note that LPS sensitivity differs
Table 5 | Comparison of the LPS dose required to induce physiological
changes across species, relative to the LPS dose required in humans.
Threshold of
physiological
changes
Severe sepsis or
lethal dose
Humans 1–5 ng/kg (i.v.)
Chimpanzees 1–5 ng/kg (i.v.)
Baboons and old
world monkeys
0.1–6 mg/kg (i.v.)
Rabbits 2–4 ng/kg (i.v.) 5 mg/kg (i.v.)
Swine 10µg/kg (i.v.) (30% of animals)
Mice 0.5 mg/kg (i.p.) 8 mg/kg (i.p.)
Rats 15 mg/kg (i.p.) to 40 mg/kg (i.v.)
considerable at the whole-organism level among species (Table 5).
Whereas characteristic symptoms of sepsis occur in humans (98)
and chimpanzees (99) following an exposure to only 1–5 ng/kg
LPS, in baboons and old world monkey species induction of sepsis
requires a dose of 0.1–6 mg/kg LPS (100). Rabbits are as sensitive
as humans to LPS since 2–4 ng/kg LPS induces an increase in body
temperature defined as the threshold level of sepsis symptoms by
the United State Pharmacopeia (101). In rabbits, an endotoxin
dose of 1–3µg/kg by intravenous route results in a cardiovascular
hyperdynamic state (102), whereas a higher dose at 5 mg/kg leads
to a hypodynamic state, that is, a severe septic shock (103). In con-
trast, swine appears heterogenic in response to LPS. Administra-
tion of 10µg/kg LPS by intravenous route induces a hyperdynamic
state in 70% of the animals but a hypodynamic state or fatal septic
shock in 30% of the animals (104). Dogs appear similar to swine in
the sensitivity to LPS since the dose required to induce a hyperdy-
namic state is also around 10µg/kg by intravenous injection (105).
Finally, mice and rats are highly insensitive to LPS. Indeed, mice
require an intraperitoneal LPS dose of 0.5 mg/kg to cause body
temperature increase (106), while intraperitoneal administration
of 8 mg/kg of LPS is lethal (107). Rats show a hyperdynamic state of
sepsis following an intravenous exposure to 3 mg/kg of LPS (108).
An intraperitoneal dose of 15 mg/kg of LPS leads to 90% mortality
in rats within 48h following exposure (109) and an intravenous
dose of 40 mg/kg of LPS induces a hypodynamic state with 100%
lethality within 24 h (110).
The divergence in LPS responsiveness between species may par-
tially be attributed to different cytokine production patterns. For
instance, LPS exposure of baboon total blood leukocytes induces
a high level of CXCL2 mRNA and low levels of CXCL8 and CCL3
mRNAs (99). In contrast, stimulated human and chimpanzee
leukocytes express high levels of CXCL8 and CCL3 and a low level
of CXCL2. Compared to human cells, at the mRNA level, chim-
panzee and baboon total blood leukocytes produce similar TNF-α
and IL-10 but higher IL-1β in response to LPS. The level of IL-6
mRNA produced after LPS stimulation is lower in baboon blood
leukocytes than in human and chimpanzee leukocytes.
Moreover, it has been noted that the immune response induced
by LPS exposure is regulated in an age-dependent manner in
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humans and macaques, an old world monkey species. When
humans are considered, cytokine synthesis in whole blood cells
following LPS exposure has been reported to be generally lower in
infants than in adults (111). Cord blood cells stimulated with LPS
produced lower amounts of TNF-α, IP-10, IL-12p70, and IFN-γ
than those produced by stimulated blood cells from adults. In con-
trast, stimulated cord blood cells produced higher amounts of IL-6,
IL-8, and IL-10 than those produced by adult blood cells and IL-
1β synthesis remained relatively constant across cord, infant, and
adult blood samples. A TLR9 agonist (e.g., CpG) did not induce the
same pattern of cytokine release, arguing for a TLR4-dependent
LPS effect. When macaques are considered, the numbers of TNF-
α or IL-6 secreting myeloid DCs and of IL-6 secreting monocytes
are significantly lower in older macaques than in adult macaques
(71). In contrast, the numbers of TNF-α secreting monocytes are
significantly higher in aged macaques than in adult animals.
CONCLUDING REMARKS
Vertebrate TLRs are highly conserved in their coding sequences,
functions, and signaling pathways across species (112). As
expected, NHPs have greater similarity to humans than other ani-
mal species regarding TLR4 gene and protein sequences, as well
as its regulation, down-stream signaling, and function. Although
substantial differences exist even between closely related primate
species, NHPs are probably the most relevant animal model for
the prediction of human responses stimulated by TLR4 agonists.
Nonetheless, ethical and financial considerations limit the use of
NHPs for routing pre-clinical vaccine evaluation.
The mouse is the most commonly used animal model for vac-
cine pre-clinical pharmacology studies. Therefore, it is extremely
important to be aware of the inherent limitations pertaining to
mouse studies as highlighted in this review and by others (10).
One should also take into account the differences in the TLR4 sys-
tems of various laboratory mouse strains. Such mouse strains as
C3H/HeJ and C57BL/10ScCr may not be appropriate especially if
the study is designed to assess the effect of TLR4 agonists, due to
their genetic defects in the TLR4 locus or in the regulation of the
TLR4 gene.
Ample studies have illustrated in humans and mice the expres-
sion patterns and functions of TLR4, thus allowing an extensive
comparison between the two species. Unfortunately, available
information is much sparse for other animal species such as rats,
rabbits, swine, and dogs regarding the properties of TLR4. Exist-
ing evidence suggests that rabbits and swine may be closer to
humans than mice concerning TLR4 sequences and its function.
In this regard, humans are highly sensitive to LPS with physiolog-
ical changes induced by a dose at nanogram per kilogram; swine
and rabbits are moderately sensitive to LPS whose physiological
changes can be induced by a dose at the microgram per kilo-
gram range; and mice are highly resistant to LPS with physiological
changes induced by a dose at milligrams per kilogram (99, 113).
However, one should take caution not to over-interpret the
TLR4 similarities or differences reviewed in this article. It is prob-
able that some disparate features seen are attributed to different
experimental settings and materials employed in various studies.
It has been reported, for example, LPS of different bacteria do
not stimulate the same array of cytokine production in a whole
blood assay (114). In future, with the prevalence of new genera-
tion “omics” technologies, studies can be performed beyond the
assessment of a specific pathway in a particular pre-clinical model.
Efforts are needed to research in different species for those com-
mon elements induced by a similar TLR4 stimulation, preferable
using a well-defined high purity TLR4 agonist. Cross-analyses of
human data with results from animal studies using a system biol-
ogy approach can potentially identify those parts in the animal
responses that are relevant for humans, thus defining predictive
biomarkers and to further refine the animal models used for non-
clinical assessment of TLR4 agonists. Such investigations could
greatly enhance our ability to translate non-clinical results into
accurate predictions of clinical outcomes, in terms of both product
efficacy and potential toxicity.
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